Immunotech Laboratories, Inc. (IMMB)

OTCMKTS · Delayed Price · Currency is USD
0.0002
+0.0001 (100.00%)
At close: Feb 18, 2026
100.00%
Market Cap 114.99K
Revenue (ttm) n/a
Net Income (ttm) -977.57K
Shares Out 574.96M
EPS (ttm) -0.02
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 67,000
Average Volume 82,313
Open 0.0002
Previous Close 0.0001
Day's Range 0.0002 - 0.0002
52-Week Range 0.0001 - 0.0002
Beta -124.13
RSI 52.61
Earnings Date n/a

About Immunotech Laboratories

Immunotech Laboratories, Inc. develops and commercializes proprietary proteins for use in treating human immunodeficiency virus (HIV), acquired immune deficiency syndrome (AIDS), hepatitis, and other immuno-related disorders. Its flagship compound is ITV-1 (immune therapeutic vaccine), a suspension of irreversible pepsin fraction that is used in the treatment of HIV/AIDS and Hepatitis C, as well as to modulate the immune system. The company is headquartered in Monrovia, California. As of June 14, 2017, Immunotech Laboratories, Inc. operates as ... [Read more]

Industry Biotechnology
Sector Healthcare
Employees 4
Stock Exchange OTCMKTS
Ticker Symbol IMMB
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.